News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Hollander David
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Hollander David (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC|
Txns:
| Granted options to buy
@ $0.5677, valued at
$0 |
|
| 03/07/2023 |
4
| Hollander David (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC|
Txns:
| Granted 8,000 options to buy
@ $3.83, valued at
$30.6k
|
|
| 02/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/23/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/15/2021 |
4
| Hollander David (Chief R&D Officer) has filed a Form 4 on AERIE PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 2,162 shares
@ $12.06, valued at
$26.1k
|
|
| 02/08/2021 |
4
| Hollander David (Chief R&D Officer) has filed a Form 4 on AERIE PHARMACEUTICALS INC|
Txns:
| Granted 11,000 shares
@ $0
Granted 50,000 options to buy
@ $17.64, valued at
$882k
|
|
| 11/12/2020 |
4
| Hollander David (Chief R&D Officer) has filed a Form 4 on AERIE PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 2,162 shares
@ $13.05, valued at
$28.2k
|
|
| 11/13/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/13/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|